A detailed history of Armstrong Advisory Group, Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Armstrong Advisory Group, Inc holds 144 shares of NTLA stock, worth $3,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares
144
Holding current value
$3,587
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 08, 2025

BUY
$9.88 - $17.76 $1,422 - $2,557
144 New
144 $2,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.89B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Armstrong Advisory Group, Inc Portfolio

Follow Armstrong Advisory Group, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armstrong Advisory Group, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Armstrong Advisory Group, Inc with notifications on news.